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Interchangeability of Generic Drugs:
A Nonparametric Pharmacokinetic Model
of Gabapentin Generic Drugs
Pieter J. Glerum1,2, Yang Yu1, Walter M. Yamada3, Michael N. Neely3, Marc Maliepaard1,
David M. Burger4 and Cees Neef5
Substitution by generic drugs is allowed when bioequivalence to the originator drug has been established. However, it is
known that similarity in exposuremay not be achieved at every occasion for all individual patients when switching between
formulations. The ultimate aim of our research is to investigate if pharmacokinetic subpopulations exist when subjects are
exposed to bioequivalent formulations. For that purpose, we developed a pharmacokinetic model for gabapentin, based on
data from a previously conducted bioavailability study comparing gabapentin exposure following administration of the
gabapentin originator and three generic gabapentin formulations in healthy subjects. Both internal and external validation
confirmed that the optimalmodel for description of the gabapentin pharmacokinetics in this comparative bioavailability
study was a two-compartmentmodel with absorption constant, an absorption lag time, and clearance adjusted for renal
function, in which eachmodel parameter was separately estimated per administered formulation.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Interchange of bioequivalent formulations can for an indi-
vidual still result in high ratios for AUC and/or Cmax, outside
the 80.00–125.00% margin.
WHAT QUESTION DID THIS STUDY ADDRESS?
 We are investigating those individual deviations by pharma-
cokinetic modeling and simulation, to challenge the appropri-
ateness of the current bioequivalence requirements in regulatory
approval of drugs.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 A pharmacokinetic model of four different gabapentin for-
mulations was developed and validated, which could aid in the
research into the interchangeability of generics.
HOW THIS MIGHT CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE
 Ultimately, our research could lead to increased trust in the
use of generic medicines, either by confirming the appropriate-
ness of the bioequivalence assessment, or by identifying issues
for potential process improvement.
Generic medicines are drugs comparable to their originator coun-
terparts, containing similar amounts of active substance(s).
Generic drugs can only be marketed when pharmaceutical com-
parability to the originator has been demonstrated and the patent
of the originator has expired. Financial investment for the devel-
opment of generic drugs is markedly lower as compared to that
for development of a new active substance medicinal product
(i.e., originator drug), as there is no need to repeat the studies on
safety and efficacy of the active substance. Therefore, generic
drugs are usually sold for lower prices, generally resulting in
healthcare cost savings.
About 80% of all pharmacy-filled prescriptions in the United
States are filled with generic drugs.1 In Europe, market shares of
generic drugs may differ between countries.2 In the Netherlands,
72.4% of all drug prescriptions in 2015 were for generic drugs,
while these accounted only for 16.5% of total drug-associated
costs.3 If available in the Netherlands, 97.1% of the prescriptions
are filled with generic drugs. This high percentage in the Nether-
lands is presumably partly a result of the way health insurance
companies execute national law and in the case of drug shortages,
pharmacists are often forced to substitute with other equivalent
(generic) drugs.4,5
Registration of generic drugs requires proof of bioequivalence
to the originator. If generic drugs contain an equal amount of
active substance(s), proof of bioequivalence can be provided by
statistically confirmed comparable bioavailability. Bioequivalent
formulations are subsequently expected to demonstrate essentially
similar efficacy and safety under identical circumstances.
Even though evidence for clinical inequivalence could not be
identified for cardiovascular and antiepileptic drugs,6–8 a large
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portion of patients and healthcare professionals have doubts
regarding quality, safety, and efficacy of generic drugs and hold a
negative opinion towards generic drug substitution.9 For
instance, in the field of epilepsy many issues regarding seizure
control are reported and various clinical guidelines recommend
to avoid generic drug substitution.10
To demonstrate bioequivalence, usually a randomized cross-
over study with pharmacokinetic endpoints is conducted, com-
paring two formulations, of which one is the originator.
Bioequivalence is confirmed when 90% confidence intervals
(CIs) of the geometric mean ratios for area under the curve
(AUC) and peak concentration (Cmax) are within prespecified
limits, which are normally 80.00 to 125.00%, as for instance
described in the “guideline on the investigation of bio-
equivalence” by the European Medicines Agency (EMA)11 and
the draft guidance “bioequivalence studies with pharmacokinetic
endpoints for drugs submitted under an ANDA” by the US
Food and Drug Administration (FDA).12 The bioequivalence
approach, however, is based on average values and only accounts
partially for the variation observed for an individual’s pharmaco-
kinetic parameters. In theory, high ratios for AUC and/or Cmax
outside the 80.00–125.00% margin could be observed upon
administration of different formulations in a single individual,
even though these formulations were proven to be bioequivalent.
Ultimately, we want to investigate those individual deviations and
to challenge the appropriateness of the current bioequivalence
requirements in regulatory approval of drugs, by investigating
whether pharmacokinetic subpopulations exist, demonstrating
low or high ratios for AUC and/or Cmax when exposed to bio-
equivalent formulations of gabapentin, using a nonparametric
pharmacokinetic modeling approach. The study described in this
article represents the first step in which we build and validate a
pharmacokinetic model for gabapentin based on pharmacokinetic
data from a previously conducted comparative bioavailability
study comparing gabapentin exposure following administration
of the gabapentin branded formulation and three generic gaba-
pentin formulations currently marketed in the Netherlands.
RESULTS
In the first step of the modeling, four different structural models
were considered. By addition of a Tlag (lag time) in the one-
compartment with absorption constant model, the Akaike Infor-
mation Criterion (AIC) decreased (–219) (Table 1). Likelihood
of the model with a second compartment was higher compared
to the one-compartment model; the AIC was reduced (AIC
from 3802 to 3669). Model fit further improved with the Tlag
introduced in the two-compartment model, with no significant
changes in bias and precision. Overall, a reduction of the AIC of
233 was observed by introduction of the second compartment
and Tlag parameters. Based on AIC, bias and precision, as well as
the visual predictive checks (VPCs), it was concluded that a two-
compartment model with addition of Tlag best explained the
observed data. The regression equation of the observed vs. the
predicted concentration is y5 0.997x1 0.0295 with an R2 of
0.887 (bias: –0.0194 and imprecision: 0.851).
The second step in this modeling exercise was refinement to
include structure with regard to the four different formulations.
Based on the chosen base model (two-compartment, Ka, Tlag) a
comparison to three additional models was made. These models
were 1) separation of Ka per formulation, 2) separation of Tlag
per formulation, and 3) separation of all parameters (Ka, Tlag, V,
KCP, KPC, and Ke) per formulation. Numerical results of this
comparison are depicted in Table 1 and show that model fit was
improved by allowing separate estimates for Ka per formulation
but not when allowed for separation on Tlag. The likelihood of
the model was strongly improved for the “pseudo subject” model,
in which each parameter was independently estimated per treat-
ment period, the AIC was reduced by 1981 (from 3569 to 1588),
Table 1 Model selection statistics
Model Parameters AIC DAIC Bias Imprecision
Structural models
1 comp1Ka Ka, V, Ke 3802 0.0018 0.8543
1 comp1Ka1 Tlag Ka, Tlag, V, Ke 3583 2219 20.0114 0.8467
2 comp1Ka Ka, V, Ke, KCP, KPC 3669 2133 0.0103 0.8638
2 comp1Ka1 Tlag Ka, Tlag, V, Ke, KCP, KPC 3569 2233 0.0194 0.8514
Level of separation
Separation of Ka Ka1, Ka2, Ka3, Ka4, Tlag, V, Ke, KCP, KPC 2546 21023 20.0052 0.8284
Separation of Tlag Ka, Tlag1, Tlag2, Tlag3, Tlag4, V, Ke, KCP, KPC 3576 17 20.0362 0.8540
All parameters separated (’96 pseudo subjects’) Ka, Tlag, V, Ke, KCP, KPC 1588 21981 20.0214 0.7888
Covariate selection
Weight Ka, Tlag, V, Ke, KCP, KPC 1613 125 20.0884 0.8063
Renal Ka, Tlag, V, Ke, KCP, KPC 1585 23 20.0280 0.7795
Weight1Renal Ka, Tlag, V, Ke, KCP, KPC 1600 112 20.0653 0.8262
Akaike Information Criterion (AIC), bias (mean error), and imprecision (mean squared error) are shown.
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compared to no separation at all. Therefore, this model was cho-
sen as the final structural model for further refinement. The
regression equation of the observed vs. the predicted concentra-
tion for this model is y5 0.995x1 0.022 with an R2 of 0.98
(bias: 20.0214 and imprecision: 0.7888).
The third step in the model-building process was covariate
selection. Based on stepwise linear regressions, weight and renal
function were selected as the covariates with the potential to
improve model fit. Weight (mean 71.0, range 52.7–97.0 kg) was
tested as a multiplicative term on V (Equation 1).
Equation 1: Weight as a multiplicative term on V.
V05V  WEIGHT
Renal function was estimated by creatinine clearance (mean 120,
range 71.2–183ml/min), which was estimated from the serum
creatinine concentration, by using the Cockcroft–Gault equa-
tion. There is no indication that gabapentin undergoes metabo-
lism in humans. Instead, it is eliminated unchanged solely by
renal excretion.13 A multiplicative term of renal function (CrCl)
on the renal clearance (Kr) is therefore expected to adequately
represent clearance (Ke) (Equation 2).
Equation 2: Clearance (Ke) as a multiplicative term of renal
function (CrCl) on renal clearance (Kr).
Ke5Kr  CrCl
From Table 1; the covariate weight as a multiplicative term on V
did not significantly improve the likelihood of the model (AIC
125), indicating no significant dependency of volume of distri-
bution on weight. However, the model fit improved with renal
function correlated with gabapentin clearance by a multiplicative
function of renal function on the elimination constant. An AIC
reduction of 3 was computed, when renal function on elimina-
tion was included in the model. A combination of both weight
on volume and renal function on clearance did not further
improve model fit (AIC1 12) relative to the model with renal
function only.
Thus, the final model for description of the gabapentin phar-
macokinetics in the bioequivalence study was a two-
compartment model with absorption constant, an absorption lag
time, and elimination adjusted for renal function in which each
model parameter was separately estimated per administered for-
mulation (Equation 3).
Equation 3: Final model equations.
ðdelta=delta TÞ ammnt depot5 Fabs  doseðT2TlagÞ
2Kaammnt depot
ðdelta=delta TÞ ammnt blood5 ammnt depot  Ka
1 ammnt peripheral  KPC2 ammnt blood 
ðKPC1KeÞ
ðdelta=delta TÞ ammnt peripheral5KCP  ammnt blood
2KPC  ammnt peripheral
concentration blood5 ammnt blood= vol blood
Ke5Kr  CrCl
error 5 sqrtðlambda21 sigma2Þ
sigma5C01C1X central
The observed vs. the predicted concentration plots are shown in
Figure 1, both for the population prediction and the individual
prediction. The regression equation is y5 0.995x1 0.0256 with
an R2 of 0.98 (bias: –0.0280 and imprecision: 0.7795).
Residual plots for the final model are shown in Figure 2.
Weighted residuals demonstrate an even spread over the concen-
tration range as well as over the time span. A slight tendency can
Figure 1 Population (left) and individual (right) predicted vs. observed values for the final two-compartment model with absorption constant, an absorp-
tion lag time, elimination adjusted for renal function, and all parameters separately estimated per formulation, line of identity (dashed line), and linear
regression (solid line). [Color figure can be viewed at cpt-journal.com]
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be observed, with some underpredictions in the lower concentra-
tion range. However, as can be seen from the histogram of resid-
uals, the majority of residuals are centered around zero. The
D’Agostino–Pearson test for nonnormality tests was not signifi-
cant (P5 0.587); thus, the assumption is made that the residual
error follows a normal distribution.
A VPC was performed for the final model, as depicted in
Figure 3. The scatterplot VPC with prediction intervals shows a
good correlation but some added variability on the distribution
and elimination phase. An overview of estimated pharmacoki-
netic parameters from both the observed concentrations and
from predicted time-observation profiles is provided in Table 2.
Despite a small underprediction of the model concentrations
(mean deviation from Cmax: 7.95%, AUC0-t: 5.08%, AUC0-inf:
6.23%) and some added variability on half-life (mean6 SD,
observed: 8.24h6 2.82, predicted: 8.846 10.67), no obvious
deviation is observed for the parameters.
Estimated pharmacokinetic parameter values obtained with the
final model are tabulated in Table 3.
Parameter values are summarized as median and the 95% CI
around the median, as calculated by a probability-weighted
Monte Carlo simulation (n5 1,000) from the support point
Figure 2 Residual plots; weighted residuals (predicted – observed) vs. predictions (left), weighted residuals (predicted – observed) vs. time (middle) and
a histogram of residuals with an overlay of a normal curve (right). [Color figure can be viewed at cpt-journal.com]
Figure 3 Scatterplot VPC, observed data from the study is represented in circles, prediction intervals (quantiles 0.05, 0.5, and 0.95) determined from
1,000 simulations as solid lines. [Color figure can be viewed at cpt-journal.com]
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distribution. The between occasion variability (BOV) is calcu-
lated as the population mean from the estimates of each subjects’
four pseudo subjects coefficient of variation.
External validation of the model was performed with data
obtained from a separate pharmacokinetic (bioequivalence) study
with an oral 800mg gabapentin formulation which was submit-
ted to the Medicines Evaluation Board (MEB) in support of a
generic application. The nonparametric adaptive grid algorithm
(NPAG) distribution from the final model was used as input
(“prior”) for the external data, to construct an observed vs. pre-
dicted concentration plot, as shown in Figure 4. A high correla-
tion can be observed, with a regression equation y5 0.925x -
0.0294 with an R2 of 0.952.
DISCUSSION
Both internal and external validation confirmed that the optimal
model for description of the gabapentin pharmacokinetics in this
comparative bioavailability study was a two-compartment model
with absorption constant, an absorption lag time, and clearance
adjusted for renal function, in which each model parameter was
separately estimated per administered formulation.
The ultimate goal of our model is to perform simulations for
the identification of pharmacokinetic subpopulations or outliers
with an aberrant exposure to gabapentin outside the 80.00–
125.00% margin when switching between bioequivalent formula-
tions. Since the aim of our research is to investigate the influence
of formulation on bioequivalence, one could argue that our
model selection was biased towards a model with parameters sep-
arately estimated per formulation. However, we used a structured
method of model selection and objective assessment of the selec-
tion parameters and thereby avoid such bias. Further, by separa-
tion of all model parameters per administered formulation we
chose the most na€ıve approach to the data. Therefore, we were
able to construct the best possible model for the explanation of
these data.
Table 2 Noncompartmental analysis derived pharmacokinetic parameters Cmax AUC0-t, AUC0-inf, Tmax and T1/2 from observed con-
centrations and individual Bayesian posterior final model predicted time-observation profiles, per treatment
Formulation 1 Formulation 2 Formulation 3 Formulation 4
Cmax (mg/l) observed 5.3361.79 5.4361.86 5.4861.44 5.6261.65
Cmax (mg/l) predicted 4.9961.71 4.8761.65 5.1161.36 5.1661.52
AUC0-t (h.mg/l) observed 63.42625.72 61.55624.70 61.16620.80 62.08622.91
AUC0-t (h.mg/l) predicted 59.92624.71 58.87624.01 58.88619.83 57.92622.04
AUC0-inf (h.mg/l) observed 64.49625.68 62.39624.68 62.45620.88 63.03623.13
AUC0-inf (h.mg/l) predicted 60.18624.62 59.12623.92 59.02619.87 58.29622.01
Tmax (h) observed 4.0 (2.50-8.0) 4.25 (2.0-8.0) 3.50 (1.5-6.0) 3.75 (1.5-8.0)
Tmax (h) predicted 3.5 (1.8-8.8) 3.7 (2.2-6.4) 3.0 (1.6-6.2) 3.7 (1.6-6.0)
T1/2 (h) observed 8.1262.70 8.0862.08 9.0863.63 7.6662.63
T1/2 (h) predicted 7.6665.94 7.9266.85 7.5364.25 12.24618.81
All parameters are mean6SD, but Tmax median and range.
Table 3 Estimated parameter values for the final model,
weighted median, 95% confidence interval around the median
(CI) and between occasion variability, % (BOV)
Parameter wMedian and 95% CI BOV
Ka (h21) 0.26 (0.23–0.31) 35%
Tlag (h) 0.30 (0.21–0.35) 75%
V (l) 90.0 (83.5–106) 34%
KCP (h21) 0.16 (0.12–0.36) 110%
KPC (h21) 0.82 (0.30–1.69) 68%
Ke (h21) 0.32 (0.29–0.36) 34%
Ke recalculated from rate per ml/min creatinine clearance.
Figure 4 Individual predicted vs. observed values from separately
obtained gabapentin validation data (800 mg bioequivalence study). [Color
figure can be viewed at cpt-journal.com]
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The rationale for the models with separation only of Ka and
Tlag is based on the general assumption regarding generic drugs
that only the absorption phase and not the distribution or elimi-
nation phase is influenced by possible formulation differences.
However, a limitation of those models is that the parameters for
the distribution and elimination phase are fixed to the same
value, for each subject. This is not an adequate representative for
the true values of these parameters, as natural variability between
occasions is expected to be present in any study, even where sub-
jects serve as their own controls. By allowing separation of all
parameters of the absorption, distribution, and elimination phase,
we allow for this interoccasion variability. An additional random-
ized 5th period in the gabapentin study, with a repeated adminis-
tration of one of the four formulations, solely dissimilar by
occasion, would have allowed computing an estimation of the
true interoccasion variability directly derived from the pharmaco-
kinetic data. With the current study design, which is the usual
for regulatory establishment of bioequivalence, it is not possible
to separate variability due to occasion vs. variability from formu-
lation. However, the absence of a “true” estimation of the inter-
occasion variability is not necessarily a weakness of the data and
the model. Within the current “pseudo subject” model, the inter-
occasion variability is not fixed to the amount we would have
computed based on repeated administration of one formulation
between two occasions. This model is without any assumptions
on the interoccasion variability.
Population pharmacokinetic models can be statistically classi-
fied as parametric or nonparametric. We choose to perform non-
parametric population pharmacokinetic modeling, even though it
is common practice to use parametric modeling in drug develop-
ment and evaluation. In drug application dossiers submitted to
regulatory authorities, the parametric program NONMEM is the
most frequently used. However, an advantage of the nonparamet-
ric approach is that no assumptions are made with regard to the
distribution of described parameter values. Entire joint distribu-
tions with probabilities are estimated based on the data, instead
of estimating a parameter mean or median (population standard
value “Theta”) and deviation (individual random effect “Eta”).14
The absence of those assumptions in the nonparametric approach
allows discovery of non-prespecified subpopulations. This theo-
retical characteristic of nonparametric modeling was confirmed
by Neely et al., by accurately detecting a bimodal elimination and
one pharmacokinetic outlier.19 Considering the aim of our study,
it is justified that nonparametric modeling is the most appropri-
ate method, optimizing our chances of identifying pharmacoki-
netic subpopulations.
Model uncertainties
The polynomial coefficients for the error model should ideally be
determined by the bioanalytical lab based on observed variation
at standard concentrations. However, in the absence of detailed
information about the accuracy and precision of this bioanalytical
method, we estimated the error polynomial coefficients based on
data from other bioanalytical gabapentin methods seen in regis-
tration files of the MEB. The chosen polynomial coefficients rep-
resent a coefficient of variation between 2.75–0.95%. The
Lambda term was fitted by NPAG in the final model to be
0.2990, indicating a low amount of process noise and a well-
executed pharmacokinetic characterization.
Gabapentin has been modeled before, using a combined
approach of parametric (NONMEM) and nonparametric model-
ing.15 The final model from this study was a one-compartment
model with a fixed absorption constant (0.44 h21) and a nonlin-
ear bioavailability parameter. Our final model deviates from the
previously described model by the absence of a function for the
absorption, an additional distribution compartment, and renal
function correlated clearance. An explanation for reaching
another optimal model could be the richer data input (i.e., 96
occasions of 17 blood samples each in our case vs. 25 occasions of
10 blood samples each in the previous study). In our research,
nonlinearity of the bioavailability was not explored, as only one
dose strength was administered. The estimated Ka in our study
(median 0.26, range 0.11–1.09 h21) was within the same extent.
Another parametric model found a one-compartment model
with absorption constant (0.053–0.461 h21) and lag time (0.48–
2.29 h21), with covariates creatinine clearance and race (Black vs.
other) on gabapentin clearance and weight and population
(healthy subjects vs. patients) on volume of distribution.16 Again,
an explanation of the observed differences could be a richer data
input compared to this study (average 1.6 samples per patient).
In addition to Ka and Tlag, a relative bioavailability term (F,
proportion) was explored to be included in the model. Due to
the high correlation of F with Ka and the inability to accurately
estimate F in the absence of intravenous data, it was concluded
to estimate Ka and treat F as a fixed (but random) population
parameter, to avoid unnecessary complication of the estimated
absorption. As an alternative, it was planned to estimate F as a
relative term. The F could then be estimated relative to one of
the formulations, but this became irrelevant with the introduc-
tion of the “pseudo subject” model.
Creatinine clearance was used to estimate renal function using
the Cockcroft–Gault equation. Although validity of the estima-
tion by Cockcroft–Gault is questioned in certain patient popula-
tions such as elderly and overweight subjects,17 we believe this is
an accurate estimator for our data, which was obtained in young
healthy adult volunteers with normal weight (included subject
were in the age range of 21–55 years and their mean BMI was in
the range of 19.9–30.0 kg/m2).
The external validation was performed using a gabapentin
dataset obtained from the registration files of the MEB. In this
study, no serum creatinine values were presented. To allow for a
Cockcroft–Gault estimation of the creatinine clearance, average
serum creatinine values (male and female) from the four-way
study were used. This was believed to be the best available esti-
mate of renal function. With the external data, a high correlation
was observed and external validation of our model could be
inferred.
To conclude, gabapentin pharmacokinetic data was shown to
be best described by a two-compartment model with an absorp-
tion constant and absorption lag time, with clearance adjusted
for renal function and each model parameter separately estimated
per administered formulation. The final model adequately
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describes the observed data, does not show deviating trends in
the goodness of fit diagnostics, and is in line with current phar-
macokinetic gabapentin knowledge. The model as described is
considered fit for further analyses and simulations. Such future
simulations using the model will be aimed to identify a potential
subpopulation of individual patients with increased risk for
altered pharmacokinetics as a result of switching between bio-
equivalent formulations.
METHODS
Gabapentin pharmacokinetic data
Gabapentin pharmacokinetic data were previously gathered in a four-
way crossover comparative bioavailability study, comparing four different
oral immediate release formulations of 800mg gabapentin that were pre-
viously accepted to be bioequivalent and therefore registered by the
Dutch MEB.18 In that study, 24 healthy volunteers (14 females and 10
males) were enrolled and completed the study. The mean age was 35
years (range: 21–55), mean body mass index was 23.6 kg/m2 (range:
19.9–30.0), and mean creatinine clearance 120mL/min (range: 71.2–
183.3). Gabapentin levels were measured in plasma samples, drawn pre-
dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 36, and 48 h
postdosing, during each period. Adverse events and vital signs were mon-
itored and standard laboratory evaluations were performed. Pharmacoki-
netic parameters Cmax AUC0-t, AUC0-inf, Tmax, T1/2, Kel, and AUC0-t /
AUC0-inf were computed and an analysis of variance (ANOVA) was per-
formed using ln-transformed Cmax, AUC0-t, and AUC0-inf. The 90%
CIs were calculated for Cmax, AUC0-t, and AUC0-inf. Bioequivalence was
confirmed between all different formulations.
Model building in Pmetrics
A total of 1,610 concentration timepoints was included in the model-
building process. Nonparametric population pharmacokinetic modeling
was performed using the Pmetrics package (v. 1.5; Laboratory of Applied
Pharmacokinetics and Bioinformatics, Los Angeles, CA) using R (v.
3.2.2, Vienna, Austria) that uses the algebraic model solver and
NPAG.19 In NPAG, four different structural base models were com-
pared, i.e., a one- and a two-compartment model with an absorption
constant, both with or without an absorption lag time. For these com-
parisons, parameters to be estimated were absorption constant (Ka, rate,
unit per hour), absorption lag time (Tlag, hours), volume of distribution
(V, liter), elimination constant (Ke, rate, unit per hour), transfer rate
from central to peripheral compartment (KCP, rate, unit per hour), and
peripheral to central (KPC, rate, unit per hour). Boundaries for the
parameter estimates were determined based on gabapentin knowledge,
estimated values and for KCP/KPC on expected intercompartmental
clearance and volume of central and peripheral compartments. Upper
parameter boundaries were 1.25 h21 (Ka), 200 L (V), 0.008 h.ml21 (Ke),
1.5 h (Tlag), 2.0 h21 (KCP), and 2.0 h21 for KPC.
Information with regard to the formulation was incorporated in the
structural model by constructing models able to separately estimate four
different parameter values for each subject, based on the administered
formulation. A model was constructed to estimate four Ka values per
subject, four Tlag values per subject, or four different values for all esti-
mated parameters. The latter was achieved by dividing subjects’ separate
sampling visits into “pseudo” subjects for this analysis, four per true sub-
ject, thus 96 in total.
The applied error model per observation (1/erroR2) is a polynomial
equation for the SD5 0.021 0.0075*(concentration), and error5
(SD21 Lambda2)0.5. The Lambda value is a fitted term to capture extra
process noise on the observed values.
Selection of the optimal structural model was based on minimization
of bias (mean predication error) and imprecision (mean square predic-
tion error) and assessed using VPC and the reduction of the AIC.20 The
AIC is defined as (2 3 k) – 2 3 ln(L), with k for the number of param-
eters and L the likelihood. Scatterplot VPCs are with prediction intervals
(quantiles 0.05, 0.5, and 0.95) from simulation (n5 1,000). Selection of
covariates (available covariates in the dataset were serum creatinine
(both at predose screening and at follow-up), age, sex, race, weight, and
height) to be included in the model was based on linear regression of
each subject’s covariates vs. the Bayesian posterior parameter values.
Inclusion of these covariates in the final model was based on the same
selection criteria as the structural model selection.
Model evaluation
Internal validation was tested by residual error plots and the D’Agostino–
Pearson test21 for normality in distribution of the residuals, as imple-
mented in Pmetrics. Noncompartmental analysis derived pharmacokinetic
parameters Cmax AUC0-t, AUC0-inf, Tmax, and T1/2 (computed by the
“makeNCA” function in Pmetrics) from both the observed concentra-
tions and from individual Bayesian posterior predicted time–observation
profile were compared.
External validation of the model was performed using a dataset from
an independent pharmacokinetic study as filed during registration at the
MEB for another generic formulation of gabapentin. In this study, sub-
jects received a single oral formulation of 800mg and plasma gabapentin
concentrations were determined predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6,
8, 12, 16, 24, 26, 48, and 60 h postdosing. This external validation was
performed using 352 concentration timepoints. A total of 22 subjects
were included in the analysis, of which there were 14 males and 8 females.
The mean age was 35 years (range: 23–47 years), and their mean body
mass index was 23.3 kg/m2 (range: 19.2–26.9 kg/m2).
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